About us

Biotech Insider is a financial media publication covering biotechnology, pharmaceuticals and the life-science markets for American investors. We publish continuously through the trading day, focusing on the catalysts that actually move the sector: clinical trial readouts, FDA decisions, licensing and M&A activity, and the long-running scientific shifts reshaping medicine.

What we cover

Our coverage is organised around continuing topics rather than one-off stories, because the questions that matter to investors rarely resolve in a single news cycle. You can follow any of them from our topics index — from gene therapy and oncology pipelines through to drug pricing, biotech financing and the AI-in-drug-discovery boom.

Who we're for

We write for people who manage their own money and want to understand what a data release or a policy shift actually means, without a terminal subscription or a finance degree. We explain mechanisms rather than simply reporting numbers.

How we work

We're direct about how this publication is produced. Our editorial policy sets out our production process, our sourcing standards and what we will and won't do. Our corrections policy explains how to tell us when we've got something wrong, and what happens next.

Contact

Biotech Insider is published by Market Equities Limited. You can reach us at our contact page.